Compare BNTX & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTX | ZBH |
|---|---|---|
| Founded | 2008 | 1927 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 19.5B |
| IPO Year | 2019 | 2001 |
| Metric | BNTX | ZBH |
|---|---|---|
| Price | $88.79 | $85.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 21 |
| Target Price | ★ $133.46 | $101.00 |
| AVG Volume (30 Days) | 855.0K | ★ 2.6M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $8,231,500,000.00 |
| Revenue This Year | N/A | $4.96 |
| Revenue Next Year | $3.37 | $3.76 |
| P/E Ratio | ★ N/A | $68.68 |
| Revenue Growth | N/A | ★ 7.20 |
| 52 Week Low | $79.81 | $79.12 |
| 52 Week High | $124.00 | $108.29 |
| Indicator | BNTX | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 47.27 |
| Support Level | $84.78 | $79.48 |
| Resistance Level | $112.44 | $102.52 |
| Average True Range (ATR) | 3.11 | 2.17 |
| MACD | -1.20 | 0.28 |
| Stochastic Oscillator | 7.03 | 83.57 |
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.